Seres Therapeutics Shares Are Trading Lower After Chardan Capital Downgraded the Stock From Buy to Neutral.
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6
Seres Therapeutics Analyst Ratings
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics' Positive Earnings Call: Progress and Challenges
Seres Therapeutics | 10-Q: Quarterly report
Seres Therapeutics Advances SER-155 Program With FDA Submission
Seres Therapeutics | 8-K: SERES THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Express News | Seres Therapeutics Inc Q1 Shr View $-0.54 -- LSEG IBES Data
Express News | Seres Therapeutics Q1 EPS $3.75 Beats $0.12 Estimate
Seres Therapeutics 1Q Net $32.7M >MCRB
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Earnings Preview: MCRB to Report Financial Results on May 07
Seres Therapeutics Presents Three Posters at DDW Conference
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
SERES Debuts Intelligent Safety at Auto Shanghai 2025, Setting Industry Standard and Capturing Global Spotlight
$MCRB Stock Is up 24% Today. Here's What We See in Our Data.
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025